Virological Failure and Second-Line ART

Is this virological failure or poor adherence, and what the switch should be · v1.8
← HIV Clinical Hub

  • Enter the failed first-line regimen, then the two viral loads and the adherence level.
  • Add the current creatinine clearance, the haemoglobin and the hepatitis B status, which decide the new backbone.
  • You get either a second-line regimen or the instruction to give adherence support and repeat the viral load.
  • Virological failure means 1000 copies/mL or above on two measurements three months apart, after at least six months on ART.

  • Third-line regimens, which are decided at an ART Plus centre, usually on a genotype.
  • Genotypic resistance testing, and how to read one.
  • Immunological and clinical failure as the trigger to switch. It works from the viral load, and Evidence and Pearls sets out why the other two are read as less reliable.
  • Regimens outside the six first-line combinations listed, and any paediatric regimen.
1. Failed First-Line Regimen
2. Failure Confirmation
3. Adherence Assessment
4. Current Parameters
Types of Treatment Failure
TypeDefinitionPreferred Metric
VirologicalVL > 1000 copies/mL on 2 consecutive samples 3 months apart, after ≥ 6 months on ARTGold standard. Primary trigger for switch.
ImmunologicalCD4 falls to (or below) pre-ART level, or persistent CD4 < 100 after 6 months, or 50% fall from peakLess reliable. May lag 6 to 12 months behind VL failure.
ClinicalNew or recurrent WHO Stage 4 event after 6 months on ARTLeast reliable. Must exclude IRIS. Only use if VL is unavailable.
1. Adherence Assessment Before Switch
NACO mandates adherence counselling before any regimen switch. A confirmed unsuppressed VL with poor adherence calls for intensive adherence support for 3 months, then a repeat VL. Switch only when the VL is still > 1000 despite good adherence. Switching before the adherence problem is addressed spends the second-line regimen on something it cannot fix.
2. Second-Line Drug Pearls
ATV/r (Atazanavir/Ritonavir 300/100mg OD): Preferred PI. Causes unconjugated hyperbilirubinaemia (scleral icterus) in up to 40%, cosmetically distressing but clinically benign. Avoid with PPIs. Atazanavir needs an acid stomach to dissolve, so acid suppression cuts its absorption. Take with food.
LPV/r (Lopinavir/Ritonavir 200/50mg, 2 tabs BD): Alternative PI. GI side effects (diarrhoea, nausea) are common and may limit adherence. Heat-stable tablets preferred over syrup. Significant metabolic effects (dyslipidaemia, insulin resistance).
Third-Line ART: Available only at designated ART Plus centres. Regimen: DRV/r 600/100mg BD + optimised backbone + RAL 400mg BD or DTG 50mg BD. Requires specialist review and often genotypic resistance testing.
Abbreviations ABC (Abacavir) · ART (Antiretroviral Therapy) · ARV (Antiretroviral) · ATV (Atazanavir) · ATV/r (Atazanavir/Ritonavir) · AZT (Zidovudine) · BD (Twice Daily) · CD4 (Cluster of Differentiation 4) · CrCl (Creatinine Clearance) · DRV/r (Darunavir/Ritonavir) · DTG (Dolutegravir) · ECG (Electrocardiogram) · EFV (Efavirenz) · FDC (Fixed-Dose Combination) · GI (Gastrointestinal) · H2 blocker (Histamine H2 Receptor Antagonist) · Hb (Haemoglobin) · HBV (Hepatitis B Virus) · HCV (Hepatitis C Virus) · HIV (Human Immunodeficiency Virus) · IAC (Intensive Adherence Counselling) · INSTI (Integrase Strand Transfer Inhibitor) · IRIS (Immune Reconstitution Inflammatory Syndrome) · LDL (Low-Density Lipoprotein) · LFT (Liver Function Test) · LPV/r (Lopinavir/Ritonavir) · NACO (National AIDS Control Organisation) · NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor) · NRTI (Nucleoside Reverse Transcriptase Inhibitor) · NVP (Nevirapine) · OD (Once Daily) · PI (Protease Inhibitor) · PPI (Proton Pump Inhibitor) · RAL (Raltegravir) · SBAR (Situation, Background, Assessment, Recommendation) · TAF (Tenofovir Alafenamide) · TDF (Tenofovir Disoproxil Fumarate) · TLd (Tenofovir + Lamivudine + Dolutegravir) · TLE (Tenofovir + Lamivudine + Efavirenz) · VL (Viral Load) · WHO (World Health Organization) · 3TC (Lamivudine)
References
  1. NACO. National Guidelines for HIV Care and Treatment. MoHFW, GoI; 2021.
  2. NACO. National Technical Guidelines on ART. 2018 (Updated 2021).
  3. WHO. Consolidated guidelines on HIV. 2021.
  4. World Health Organization. WHO updated recommendations on HIV clinical management: recommendations for a public health approach. Geneva: WHO; 7 January 2026. [First substantial revision since 2021.
How to Cite This Tool

DOIhttps://doi.org/10.5281/zenodo.22401598

AMA Style:Umakanth S. Virological Failure and Second-Line ART. Version 1.8. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/hiv-second-line-art. doi:10.5281/zenodo.22401598

Vancouver Style:Umakanth S. Virological Failure and Second-Line ART [Internet]. Version 1.8. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/hiv-second-line-art. doi:10.5281/zenodo.22401598

Disclaimer and scope
Disclaimer: This decision-support system is written for healthcare professionals. It does not substitute clinical judgment, and the treating physician retains absolute responsibility for every diagnostic, dosing and therapeutic decision. The algorithms are built on the evidence as it stands, and the evidence moves. Verify the output against your current institutional protocol, and against the patient in front of you.
© 2026 MEDiscuss.org. All rights reserved. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Therapeutic & Management PathwaysPathway
Specialties Internal Medicine, Infectious Diseases, HIV Medicine

Written and maintained by

Dr Shashikiran Umakanth

Last revised 24 August 2026

How these tools are written and reviewed

Related Clinical Tools
First-Line ART SelectionART Monitoring & ADR GuideHIV Clinical Pathway Hub